

Subject Index

- A2008/A2008C, historical perspective 4, 6, 9, 10, 11, 98, 99
- ABG-I, historical perspective 4, 6
- ABG-II, historical perspective 4
- Advanced glycation end-products (AGEs), on-line hemodiafiltration removal 103
- Backfiltration
 - definition 6, 7, 35
 - double high-flux hemodiafiltration 42
 - enhanced internal filtration hemodialysis 42, 43
 - factors affecting
 - blood and dialysate flows 39
 - fiber geometry 39
 - hematocrit 39
 - water permeability 38, 39
 - hemodiafiltration 41
 - hemofiltration with infusion 42
 - high-flux hemodialysis 41
 - historical importance 37, 38
 - low-flux hemodialysis 40
 - measurement 36, 37
 - mid-dilution hemodiafiltration 41
 - paired filtration dialysis 41
 - push-pull hemodiafiltration 42
- Blood flow (Q_b)
 - backfiltration impact 39
 - on-line hemodiafiltration 144, 180, 181
- CD14+/CD16+ monocyte
 - CD14 activation and inflammation 110, 111
 - chronic inflammation role 111, 112
 - chronic kidney disease levels 114
 - endothelial damage 113
 - on-line hemodiafiltration and cardioprotective effect 114
 - sources 113
- CHOIR trial 124
- Chronic kidney disease (CKD)
 - epidemiology 171
 - renal replacement therapy
 - blood flow 180, 181
 - clinical benefits 174
 - costs 178, 179
 - filter performance
 - optimization 181, 182
 - fluid flow rate 181
 - fluid removal 180
 - hemodiafiltration
 - inflammation reduction 177
 - intensity of dialysis 175, 176
 - needs 173
 - principles 171, 172
 - prospects 179–182
 - quality of life 177, 182–184
 - social, ethical, and financial issues 173
 - survival benefits 172, 174, 175, 182–184
- Clinical Management Europe (CME) 154

- CMPE, on-line hemodiafiltration
 - removal 103
- Continuous ambulatory peritoneal dialysis (CAPD) 29, 31
- CONTRAST study 130, 131, 148, 174
- Convection
 - contribution to solute transport 62
 - membrane performance 60–63
 - mixed dilution hemodiafiltration, *see* Mixed dilution hemodiafiltration
- C-reactive protein (CRP)
 - hemodiafiltration outcomes 32
 - RISCAVID study 123
- p*-Cresyl sulfate, on-line hemodiafiltration
 - removal 103
- Daily on-line hemodiafiltration 147, 148
- Dialysis fluid
 - hemodiafiltration 51, 52, 181
 - hemofiltration 47–51
 - high-flux hemodialysis 52–54
 - regulatory challenges 75, 76
- Dialysis Outcomes and Practice Patterns Study (DOPPS) 32, 122, 124, 158, 164, 174
- Diasafe, historical perspective 9, 10
- DIASAFE Plus 63, 155
- Directive 65/65/EEC 70
- End-stage renal disease (ESRD)
 - epidemiology 164
 - hemodiafiltration as renal replacement therapy 163–169
- Erythropoietin, resistance 123–125
- ESHOL study 148
- EuCliD 155, 156, 158, 159
- European Best Practice Guidelines (EBPG) 90, 155–158
- European Renal Best Practice (ERBP) 90
- European Union, regulatory challenges
 - for on-line hemodiafiltration 69–72, 77–80
- F-60, historical perspective 4, 24
- Filtration fraction (FF), mixed dilution hemodiafiltration 133, 135, 136
- Fresenius Medical Care (FME) 152–154, 158, 160, 164
- Fresenius systems, *see* A2008; F-60; Online plus
- Hagen-Poiseuille formula 43
- Hematocrit
 - backfiltration effects 39
 - factors affecting levels 100, 101
- Hemodiafiltration (HDF)
 - backfiltration
 - double high-flux hemodiafiltration 42
 - mid-dilution hemodiafiltration 41
 - overview 41
 - push-pull hemodiafiltration 42
 - CD14+/CD16+ monocyte response 114
 - chronic kidney disease renal replacement therapy
 - blood flow 180, 181
 - clinical benefits 174
 - costs 178, 179
 - filter performance
 - optimization 181, 182
 - fluid flow rate 181
 - fluid removal 180
 - inflammation reduction 177
 - intensity of dialysis 175, 176
 - principles 171, 172
 - prospects 179–182
 - quality of life 177, 182–184
 - survival benefits 172, 174, 175, 182–184
 - circuit 5
 - clinical rationale 33, 34
 - dialysis fluid 51, 52
 - end-stage renal disease renal replacement therapy 163–169
 - historical perspective 3, 4, 29, 30, 94–97, 142
 - infusion modes 144, 145
 - mortality 104
 - on-line systems
 - challenges for development 146
 - development 4–6, 8, 10, 12, 13, 96–103, 142–144

- prospects 104
- residual renal function 31–33
- Hemodialysis (HEMO) study 83–85, 88, 131
- Hemofiltration (HF)
 - backfiltration 42
 - dialysis fluid 47–51
 - historical perspective 1–3
- High-flux hemodialysis
 - aims 81, 82
 - backfiltration 41
 - dialysis fluid 52–54
 - mortality studies 89
- Indoxyl sulfate, on-line hemodiafiltration removal 103
- Inflammation, *see* CD14+/CD16+ monocyte; RISCAVID study
- Inflammatory cytokines
 - on-line hemodiafiltration removal 103
 - RISCAVID study 123, 124
- Infusion rate (Q_i), automated manual prescription for on-line hemodiafiltration 146, 147
- Leptin, on-line hemodiafiltration removal 103
- Lister Renal Unit (LRU) 31, 32
- Membrane fabrication, *see also specific membranes*
 - phase inversion 64, 65
 - polymer selection 65
 - principles 64
- Membrane performance, *see also specific membranes*
 - convection versus large exchange volumes 60–63
 - determinants 58, 59
 - large toxin removal versus protein leakage 58–60
 - optimization 181, 182
 - safety 63, 64
- Membrane Permeability Outcome (MPO) study
 - clinical impact 87–89
 - HEMO study comparison 85
 - outcomes 84–87, 156
 - patient characteristics 84
 - rationale 82–84
- β_2 -Microglobulin
 - Membrane Permeability Outcome study outcomes 87
 - on-line hemodiafiltration versus hemodialysis 145
 - removal 30, 33, 103, 133
- Mixed dilution hemodiafiltration
 - backfiltration 41
 - closed loop control and adaption mode 135, 136
 - convection optimization
 - membrane conditioning 132–134
 - treatment efficiency maximization 132
 - infusion modalities 131, 132
 - outcomes 136–138
 - overview 129–131
 - parameters 135
- Monocytes, *see* CD14+/CD16+ monocyte
- National Cooperative Dialysis Study (NCDS) 29
- NephroCare network 153, 157, 159, 160
- Nocturnal on-line hemodiafiltration 148
- Online Plus, historical perspective 12, 13
- Paired filtration dialysis, backfiltration 41
- Phase inversion, membrane fabrication 64, 65
- Phosphate
 - on-line hemodiafiltration removal 102
 - RISCAVID study 124–126
- Polyamide membranes, historical perspective 6, 7
- Polysulfone membranes
 - capacity 20
 - formation mechanism 21, 22
 - historical perspective 6, 7, 15–25
 - post-processing 24
 - PS 600 advantages 22, 23
 - spinning unit technical specification 19

- Q_b , *see* Blood flow
 Q_i , *see* Infusion rate
- Regulatory challenges, on-line
 hemodiafiltration
 dialysis fluid 75, 76
 European Union 69–72, 77–80
- Renal replacement therapy, *see* Chronic
 kidney disease; End-stage renal disease
- Residual renal function (RRF),
 hemodiafiltration outcomes 31–33
- RISCAVID study
 aims 120
 chronic inflammation and
 hemodialysis modality effects on
 morbidity and mortality 120, 122,
 123
- erythropoietin resistance 123, 124
patient characteristics 121
phosphate studies 124–126
- Spinning, *see* Polysulfone membranes
- Transmembrane pressure (TMP) 35, 36,
 39, 133–136, 143, 144, 146, 147
- Ultrafiltration rate 36, 138
- Vascular access, on-line
 hemodiafiltration 144